Abstract 14P
Background
Small cell lung cancer (SCLC) is a lethal neoplasia. Chemotherapy (Ct) plus immune checkpoint blockade therapy (ICBt) is now the standard of care although limited survival benefit. Lack of biomarkers of response leads to suboptimal patient selection, distorting results of clinical trials. Deciphering the ICBt-driven peripheral immune events may recognize those patients who benefit the most. Here, we characterize early peripheral immune kinetics in SCLC patients treated with Ct + ICBt with improved survival.
Methods
SCLC patients from 8 centers were prospectively recruited into 3 cohorts. Cohort 1 include patients treated with Ct (n=24). Cohort 2 (n=37) comprise patients treated with Ct + anti-CTLA-4, and cohort 3 (n=20) patients treated with Ct + anti-PD-1/PD-L1. Peripheral blood mononuclear cells were obtained prior to treatment and after the first dose of ICBt. Variation in proliferation, senescence, adhesion, immunosuppression, and checkpoints markers was assessed by FACS. Kaplan–Meier and log-rank test were used for survival analysis. MaxStat was used to calculate cut points. A p-value <0.05 was considered statistically significant.
Results
We found 6 independent cellular subsets which modulation right after the start of ICBt identify patients with improved survival. An increase in CD8+CD103+Ki67+ cells identify survival benefit in cohorts 1 and 3 (p=0.043; 0.0033). An upregulation of Ki67 in total CD4+ (p=0.012; 0.0027) and CD4+PD-1+ T cells (p=0.026; 0.027), predicts long survival in ICBt cohorts 2 and 3, while a downregulation of CD4+ICOS+ T cells (p=0.025; 0.011) identified survival benefit in these ICBt cohorts. Expansion of Ki67+ and ICOS+ (p=0.0024; 0.0074) CD8+ T cells was also observed in CD8+ T cells from long survivors exclusively from cohort 2.
Conclusions
Expansion of CD8+CD103+Ki67+, CD4+Ki67+, and CD4+PD-1+Ki67+, or a reduction in CD4+ICOS+ circulating T cells subsets identify long survival patients treated with anti-CTLA-4 or anti-PD-1/PD-L1, while an increase in CD8+Ki67+ or CD8+ICOS+ cells predicts benefit only in patients treated with anti-CTLA-4. Assessment of the immune kinetics of these peripheral cellular subsets identify patients who benefit the most from ICBt in SCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Fundació Amics de l'Hospital del Mar.
Disclosure
E. Arriola: Financial Interests, Personal and Institutional, Advisory Role, Speaker, Institutional funding, Travel and educational expenses: BMS, MSD; Financial Interests, Personal and Institutional, Advisory Role, Speaker, Institutional and Research funding, Travel and educational expenses: Roche; Financial Interests, Personal and Institutional, Advisory Role, Speaker, Institutional and Research funding: Pfizer; Financial Interests, Personal, Advisory Role, Speaker, Travel and educational expenses: Lilly; Financial Interests, Personal and Institutional, Advisory Role, Speaker, Institutional funding: AstraZeneca; Financial Interests, Personal, Advisory Role, Speaker: Boehringer Ingelheim, Takeda; Other, Personal, Member of Board of Directors, Co-founder: TrialingHealth. All other authors have declared no conflicts of interest.
Resources from the same session
68P - Dendritic polylysine with paclitaxel and triptolide codelivery for enhanced NSCLC ferroptosis through the accumulation of ROS
Presenter: Huae Xu
Session: Poster session 09
69P - Novel monoclonal antibodies can distinguish Cripto-1 from Cripto-3 proteins: Clinical implications and potential new biomarkers
Presenter: Josune Garcia-Sanmartin
Session: Poster session 09
70P - The human intratumor mycobiome is significantly influenced by an individual's race
Presenter: Dan Coster
Session: Poster session 09
71P - Preclinical characterization of ARX305: A next-generation anti-CD70 antibody drug conjugate for the treatment of CD70-expressing cancers
Presenter: Lillian Skidmore
Session: Poster session 09
72P - Impact of extended panel of genes for germline cancer testing
Presenter: Shaheenah Dawood
Session: Poster session 09
73P - Preclinical and clinical presentation of the nerve-driven tumor spread
Presenter: Dawid Sigorski
Session: Poster session 09
74P - Characterization of ERBB2 variation and their association with immune response in solid tumours
Presenter: Dong Wang
Session: Poster session 09
75P - Double-stranded RNA transfection induced anti-tumour effect mediated by dual RIG-I and TLR-3 immune pathways
Presenter: Jiayu Tai
Session: Poster session 09
76P - Improvement of whole-cell cancer vaccine anti-tumor effect by different injection methods
Presenter: Chin yang Chang
Session: Poster session 09
77P - Normative data on the sexual health questionnaires - QLQ-SHQ22, and the sexual domains of the QLQ-BR23/BR45 - for Norwegian general population with and without cancer
Presenter: Ragnhild Åsberg
Session: Poster session 09